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Background: Preliminary studies have indicated that music therapy may benefit children with autism
spectrum disorders (ASD).
Objectives: To examine the effects of improvisational music therapy (IMT) on social affect and
responsiveness of children with ASD.
Design: International, multicentre, three-arm, single-masked randomised controlled trial, including a
National Institute for Health Research (NIHR)-funded centre that recruited in London and the east of
England. Randomisation was via a remote service using permuted blocks, stratified by study site.
Setting: Schools and private, voluntary and state-funded health-care services.
Participants: Children aged between 4 and 7 years with a confirmed diagnosis of ASD and a parent or
guardian who provided written informed consent. We excluded children with serious sensory disorder and
those who had received music therapy within the past 12 months.
Interventions: All parents and children received enhanced standard care (ESC), which involved three
60-minute sessions of advice and support in addition to treatment as usual. In addition, they were
randomised to either one (low-frequency) or three (high-frequency) sessions of IMT per week, or to ESC
alone, over 5 months in a ratio of 1 : 1 : 2.
Main outcome measures: The primary outcome was measured using the social affect score derived from
the Autism Diagnostic Observation Schedule (ADOS) at 5 months: higher scores indicated greater impairment.
Secondary outcomes included social affect at 12 months and parent-rated social responsiveness at 5 and
12 months (higher scores indicated greater impairment).
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Results: A total of 364 participants were randomised between 2011 and 2015. A total of 182 children were
allocated to IMT (90 to high-frequency sessions and 92 to low-frequency sessions), and 182 were allocated
to ESC alone. A total of 314 (86.3%) of the total sample were followed up at 5 months [165 (90.7%) in
the intervention group and 149 (81.9%) in the control group]. Among those randomised to IMT, 171
(94.0%) received it. From baseline to 5 months, mean scores of ADOS social affect decreased from 14.1 to
13.3 in music therapy and from 13.5 to 12.4 in standard care [mean difference: music therapy vs. standard
care = 0.06, 95% confidence interval (CI) –0.70 to 0.81], with no significant difference in improvement.
There were also no differences in the parent-rated social responsiveness score, which decreased from 96.0 to
89.2 in the music therapy group and from 96.1 to 93.3 in the standard care group over this period (mean
difference: music therapy vs. standard care = –3.32, 95% CI –7.56 to 0.91). There were seven admissions to
hospital that were unrelated to the study interventions in the two IMT arms compared with 10 unrelated
admissions in the ESC group.
Conclusions: Adding IMT to the treatment received by children with ASD did not improve social affect or
parent-assessed social responsiveness.
Future work: Other methods for delivering music-focused interventions for children with ASD should
be explored.
Trial registration: Current Controlled Trials ISRCTN78923965.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 21, No. 59. See the NIHR Journals Library website
for further project information.
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Children with autism have problems understanding and communicating with other people. This canaffect their general development, emotional health and social relationships. Little is known about how
best to help them.
Music therapy is a treatment that aims to help children develop better communication skills and
relationships through making, listening and responding to music. A number of studies have shown
promising results, but were too small to be sure if this is really an effective approach.
The TIME-A trial was an international randomised controlled trial study of music therapy for children with
autism. We recruited 364 children with autism, aged 4–7 years, across nine countries. We offered all the
children three sessions of advice and support, then randomly selected half and offered them music therapy
as well. The music therapy was delivered either once or three times per week for 5 months. We followed
the children up at 5 and 12 months and assessed their social and communication skills, as well as the level
of stress and mental well-being experienced by their parents.
Nearly all the children who were offered music therapy attended it and, on average, 19 sessions were
attended in total. However, there were no significant differences in social and communication skills
between children allocated to the additional music therapy and those allocated to the advice and support
alone. There was also no difference in the parent’s assessment of the child’s related social responsiveness.
Despite high levels of engagement in music therapy, it does not appear to improve social communication
in children with autism. Alternative methods for delivering music-focused interventions for children with
autism should be explored.
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One out of every 100 children have autism spectrum disorder (ASD). The core features of the condition are
persistent impairment in reciprocal social interaction and social communication, together with restricted,
repetitive patterns of behaviour, interests or activities. ASD are associated with an increased risk of poor
mental health, social exclusion and reduced quality of life. The costs associated with ASD in the UK are
estimated to be > £28B per year.
The evidence base for effective early intervention is weak. Recent guidance from the National Institute for
Health and Care Excellence (National Institute for Health and Care Excellence. Autism: Management and
Support of Children and Young People on the Autism Spectrum. Clinical Guideline 170. London: National
Institute for Health and Care Excellence; 2013) emphasised advice, education and support for parents and
efforts to adjust the child’s environment to minimise the impact of their difficulties.
A systematic review in 2014 (Geretsegger M, Elefant C, Mössler KA, Gold C. Music therapy for people
with autism spectrum disorder. Cochrane Database Syst Rev 2014;6:CD004381) identified 10 small
randomised controlled trials (RCTs) of music therapy (involving 165 participants) and found evidence of
improvements in social interaction and communication. The authors concluded that music therapy may
help children with ASD, but highlighted differences in delivery between trials and normal clinical practice.
In clinical practice, most children received weekly sessions, but trials have generally tested more frequent
sessions. Another limitation is that the trials examined the impact of music therapy only while it was being
delivered. No trials have tested if any benefits persist once treatment stops.
The TIME-A study is an international multicentre RCT funded by the Research Council of Norway to
investigate the clinical effectiveness of improvisational music therapy (IMT) for children with ASD.
We obtained funding for recruitment in England.
Objectives
To examine whether or not adding IMT improves children’s social affect and social responsiveness, and to
explore whether or not any benefits are influenced by how often the treatment is offered. In the National
Institute for Health Research (NIHR)-funded arm, we also explored if music therapy was associated with
reduced stress and improved mental well-being of parents.
Methods
Study design
A three-arm, international, multicentre, Phase III RCT. Researchers conducting assessments were masked to
allocation status, but participants, their families and staff involved in their care were not.
Setting
State-funded, voluntary and private sector-funded health, educational and social care services in Australia,
Austria, Brazil, Israel, Italy, Korea, Norway and the USA. Participants for the NIHR-funded arm of the study
were recruited from schools and NHS clinics in Bedfordshire, Cambridgeshire, Essex and London.
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Target population
Children aged between 4 years and 6 years and 364 days (i.e. > 4 years but < 7 years) with a clinical diagnosis
of ASD that was confirmed using the Autism Diagnostic Observation Schedule (ADOS), and two of the three
domains of the Autism Diagnostic Interview-Revised (ADI-R). We excluded children who were already
receiving music therapy or had done so within the past 12 months, children with severe sensory disorder and
those whose parent or guardian was unable or unwilling to provide written informed consent to participate.
Health technologies being assessed
Parents/guardians (referred to as ‘parents’ in the remainder of this report) of all participants were offered
enhanced standard care (ESC) by adding three sessions of advice and support to the care they would
otherwise have received. Half of all children were also offered IMT for 5 months, either three times per
week (high frequency) or once per week (low frequency). All music therapy sessions were 30 minutes long
and delivered in accordance with consensus guidelines.
Measurement of outcomes
The primary outcome was the child’s social affect at 5 months using the social affect scale of the ADOS.
Higher scores indicated greater impairment. Secondary outcomes included social affect measured at
12 months and social responsiveness reported by parents using the Social Responsiveness Scale (SRS) at
5 and 12 months. Following feedback from parents of children with ASD in England, we also assessed
parental stress, using the Parenting Stress Index – Short Form (PSI-SF), and parental well-being, using the
short version of the Warwick–Edinburgh Mental Well-Being Scale, at 5 and 12 months in the NIHR-funded
English arm of the trial. Higher scores on the PSI-SF indicated higher levels of stress, and higher scores on the
Warwick–Edinburgh Mental Well-Being Scale indicated higher levels of mental well-being.
Study logistics
Potential participants were identified by teachers and staff working in schools who deliver specialist
education to children with developmental problems, and by clinical staff in health centres. Parents who
gave verbal consent to meet a researcher were given written and verbal information about the study.
Those willing to take part were asked to provide written informed consent to assess eligibility and to
complete baseline assessments.
Those meeting the eligibility criteria were randomised by a remote service (based in Norway) using an
allocation ratio of 1 : 1 : 2 (high-frequency music therapy : low-frequency music therapy : ESC alone). We
used block randomisation with randomised block sizes of four or eight, stratified by study centre.
Follow-up assessments were conducted 5 and 12 months after randomisation by a researcher who was
masked to the participant’s allocation status.
Sample size
We estimated that a sample of 235 participants would provide 90% power to detect a medium effect size
of the intervention in the social affect score of the ADOS at 5 months, with a 5% level of statistical
significance. To take account of clustering and loss to follow-up, we set out to recruit a minimum of 300
children and their families. We aimed to recruit 100 participants in the NIHR-funded arm of the trial to
help the international study to achieve the required sample.
Data analysis
All primary analyses were by intention to treat using two-sided tests and a 0.05 level of statistical
significance. The primary analysis compared changes in the social affect score of the ADOS between
baseline and 5 months in the pooled active arms and controls randomised to ESC. Following assessment of
normality, treatment effects were analysed using generalised estimating equations that allow for analysis
of longitudinal data while accounting for correlations among the repeated observations for each
participant. Generalised estimating equation analyses were also used to examine dose–effect relationships
and to explore possible confounding effects of site or relevant subgroups, such as age and gender.
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Results
Between November 2011 and November 2015, 702 children were assessed for eligibility, of whom 315
were excluded (n = 109 ineligible; n = 206 declined) prior to the baseline assessment, and another 23 were
found ineligible and not randomised. Among the 364 remaining participants, 182 were allocated to IMT
plus ESC (90 to high-frequency sessions and 92 to low-frequency sessions) and 182 were allocated to ESC
alone. Participating children had a mean age of 5 years and 4 months (standard deviation 0.9 years) and 302
(83.0%) were male. In total, 316 (86.8%) were followed up 5 months later. Among the 182 participants
randomised to IMT, 171 (94.0%) received it. The median number of sessions attended was 19 (35 in those
offered high-frequency therapy and 15 in those offered low-frequency therapy).
No difference in the primary outcome was found between trial arms. The mean change in social affect
scores at 5 months between the active and control arms of the trial was 0.06 [95% confidence interval (CI)
–0.70 to 0.81]. The mean difference in change in parent-reported SRS score between those randomised to
IMT and ESC was –3.64 (95% CI –7.72 to 0.94; p = 0.90).
A total of 81 participants were recruited in the NIHR-funded arm of the trial. All 41 (100%) children
randomised to IMT in the NIHR-funded arm of the trial received it. The median number of sessions
attended was 43 in the high-frequency group and 15 in those randomised to the low-frequency group.
The outcomes of participants in the NIHR-funded arm of the trial did not differ from those in the international
study. Parents of children who were randomised to music therapy reported less distress at 12 months
(difference of –3.73%, 95% CI –2.39 to – 10.86; p = 0.007); no differences were seen in parental mental
well-being. Further details of the results of the study have been published in the Journal of the American
Medical Association (Bieleninik L, Geretsegger M, Mössle K, Assmus J, Thompson G, Gattino G, et al.
Effects of improvisational music therapy versus enhanced standard care on symptom severity among
children with autism spectrum disorder: the TIME-A randomized clinical trial. JAMA 2017;318:523–4).
Implications for health care
Many children with ASD enjoy music and engage well with music therapy. However, adding IMT to other
treatments received by children aged 4–7 years with ASD does not appear to improve the core symptoms
of this disorder.
Recommendations for future research
Future research should examine alternative methods for delivering music-focused interventions for children
with ASD.
Trial registration
This trial is registered as ISRCTN78923965.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the NIHR.
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Autism spectrum disorder and impact of autism on health
Autism spectrum disorder (ASD) are lifelong developmental disabilities that affect > 600,000 people
in the UK.1 People with ASD may have severe problems communicating with others, and this can lead to
difficulties in relationships and impaired social functioning.2 These disabilities can give rise to emotional
distress and behavioural problems and increased levels of contact with health and social care services.3–5
It is estimated that > £3B a year is spent on supporting children and adults with ASD in the UK.3 Caring
for a child with ASD can be challenging, and parents of children with ASD are more likely to experience
difficulties, such as emotional distress and financial hardship.5
Problems in social interaction and communication among children with ASD normally become apparent
during the first 2 years of life.6 The average age of diagnosis of ASD is 4 years.7 The prognosis of ASD is
very varied, but the majority of people diagnosed with this condition in childhood go on to need long-term
input from services as adults.8 If successful, interventions and treatments delivered to people with ASD
during childhood have the potential to have a long-term impact on mental health, social functioning and
costs of care of people with this condition.
Interventions and treatments for autism spectrum disorder
There is no known cure for ASD and there are no effective pharmacological interventions for the core
symptoms of the condition. Although some psychotropic medications have been shown to help reduce
the extent of challenging behaviours,9 current guidance from the National Institute for Health and
Care Excellence states that psychotropic medication should not be used to manage the core features of
ASD, because the balance of risks and benefits do not favour their use.10 In recent years, a variety of
parent-mediated interventions that aim to help family carers to develop and implement successful
strategies for supporting young children’s communication and managing behaviour have shown promising
results.11 However, the authors of a 2014 Cochrane review noted that most studies to date have not
reported statistically significant evidence of changes in primary outcomes and that their impact on
children’s adaptive skills and parental stress is unclear.12
Music therapy is a form of psychosocial intervention that aims to harness the power of music to provide
an alternative means to learn about and develop communication skills and relationships. A number of
small-scale studies have generated promising results that suggest that ‘improvisational music therapy’
(IMT) for children with ASD can help to improve social communication and reduce symptoms of ASD.13–15
In IMT, the child and the therapist spontaneously co-create music using singing, musical instruments and
movement. IMT has been described as a developmental, child-centred approach in which a trained music
therapist follows the child’s focus of attention, behaviours and interests to facilitate growth in the child’s
social communicative skills and promote development in other areas.16 A Cochrane systematic review in
2014 identified 10 small randomised controlled trials (RCTs) of music therapy (involving 165 participants)
and found evidence of improvements in social interaction and communication skills.12 On the basis of
these findings, the authors concluded that music therapy may help children with ASD. However, they
highlighted differences in the approach to delivering music therapy in these trials compared with normal
clinical practice. Most children receiving music therapy in clinical practice receive weekly sessions, but most
trials tested therapy that was delivered more frequently than this. Another limitation of previous trials is
that they examined the impact of music therapy only as it was being delivered. To our knowledge, no trials
to date have examined whether or not any benefits associated with therapy persist once treatment stops.
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The TIME-A study
The TIME-A study is an international multicentre RCT of IMT for children with ASD that was funded by the
Research Council of Norway (ISRCTN78923965).17 The study set out to test the impact of 5 months
of IMT on children with ASD aged between 4 and 7 years. The study aimed to recruit a minimum of
300 children and follow them up over 1 year to compare the social affect and social responsiveness of
those offered music therapy with those offered enhanced standard care (ESC). Standard care was
enhanced by offering all parents of children in the trial three 60-minute sessions of advice and support.
Over the course of the first year of the trial, recruitment successfully started in six countries, but the rate of
recruitment was lower than required. In collaboration with the chief investigator of the international trial
(CG), we applied for additional funding from the National Institute for Health Research (NIHR) Health
Technology Assessment (HTA) programme to set up an English arm of the study, with the aim of helping
to ensure that the international trial succeeded in achieving the required sample size and increasing the
generalisability of findings to children and parents in contact with NHS services in the UK.
The NIHR-funded arm of the trial was designed in keeping with the protocol for the international TIME-A
study, with three exceptions. First, feedback from parents in England who helped us to design the protocol
led us to include an assessment of parental stress and parental mental well-being; therefore, questionnaires
assessing these outcomes were added to the study. Second, the international trial outcomes were assessed
2, 5 (primary end point) and 12 months after randomisation. However, in the NIHR-funded arm of the trial
we dropped the 2-month assessment in order to maximise the rate of recruitment into the study. Third, the
international study also set out to collect some service use data in order to explore the cost-effectiveness
of music therapy for children with ASD. We were asked to drop this component of the study and have
therefore not included any data on service utilisation or cost-effectiveness in this report. Results of the trial
have also been published in Bieleninik et al.18
Rationale for the study
Improvisational music therapy has the potential to improve social interaction and the communication skills
of children with ASD and, therefore, have an impact on the long-term prognosis of the condition. Previous
trials of this intervention have been too small to provide a precise estimate of any treatment effect and have
not examined whether or not any benefits associated with this intervention persist once treatment has
stopped. The international multicentre TIME-A trial was designed to test the clinical effectiveness of IMT over
a 1-year period. The NIHR-funded arm of the trial was designed to help ensure that the international trial
met its recruitment target and to make it easier to generalise the results of the international study to children
in contact with NHS services in the UK. In this report, we will present the methods used in the international
trial and minor differences in the design of the NIHR-funded arm of the trial, followed by the main results of
the international trial and those of participants recruited in the NIHR-funded arm of the study.
Aim and objectives
The aim of the international TIME-A study was to assess the clinical effectiveness of music therapy for
children with ASD.
The objectives were to:
1. examine whether or not adding IMT to ESC for children with ASD improves their social communicative
skills assessed by masked researchers
2. examine whether or not adding music therapy to ESC for children with ASD improves their social
responsiveness as reported by parents
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3. to explore whether or not any response to music therapy varies with how often treatment is delivered
(once-weekly therapy compared with three times per week).
In addition, in the NIHR-funded arm of the trial we explored whether or not adding IMT to ESC of children
with ASD was superior to ESC alone in reducing stress and improving the mental well-being of the parents
of children in the study.
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The TIME-A study is a three-arm, parallel-group, researcher-masked, international multicentre RCT. All
parents of children in the trial were offered ESC, which comprised usual treatment plus the offer of three
sessions of advice and support. In addition, half the study sample were randomly allocated to high-frequency
(three times per week) or low-frequency (once per week) IMT delivered over a 5-month period.
The primary outcome measure was the severity of symptoms of ASD assessed 5 months after randomisation,
using the social affect algorithm of the Autism Diagnostic Observation Schedule (ADOS).19,20
Study setting
The setting for the international trial was state-funded, voluntary and private sector-funded health,
educational and social care services in Australia, Austria, Brazil, Israel, Italy, Korea, Norway and the USA.
Participants for the NIHR-funded arm of the study were recruited from schools and NHS clinics in
Bedfordshire, Cambridgeshire, Essex and London.
Participants
Children aged between 4 and 7 years who had a clinical diagnosis of ASD and their parents. To maximise
the generalisability of the study findings, we used broad inclusion criteria and limited the exclusion criteria to
essential features that were not compatible with using the intervention or participating in the trial.
Inclusion criteria
Families were considered for inclusion if:
l the child was aged > 4 years and < 7 years
l the child had a clinical diagnosis of ASD, confirmed using the ADOS,19 and two of the three domains
of the Autism Diagnostic Interview-Revised (ADI-R).21
Exclusion criteria
Families were excluded if:
l the child had received music therapy in the last year
l the child had severe sensory disorder (we excluded children with severe visual or hearing impairment,
as this would have prevented them from being able to make full use of the music therapy)
l the parent of the child was unable or unwilling to provide written informed consent to take part in
the trial.
Recruitment
Methods of recruitment varied between countries in the international trial, but generally involved
publicising the study at specialist centres for the assessment and treatment of children with ASD. In the
NIHR-funded arm of the trial, we initially contacted clinicians working in health-care services and child
development centres, and outpatient child and adolescent mental health services. Members of the research
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team presented plans for the study at local academic and clinical meetings and asked staff to seek verbal
consent from parents of children who might be eligible to take part in the study. It quickly became evident
that it would be difficult for children to attend music therapy sessions if they were delivered anywhere
other than at the school they attended. Therefore, we changed our approach to recruitment and focused
on schools that specialised in catering for the educational needs of children with ASD and other
developmental disorders. Initially, staff at schools contacted parents of children who might be eligible and
researchers organised meetings at schools for parents of children with ASD so that they could find out
about the study.
Parents who agreed to meet a member of the study team were provided with written and verbal
information about the study, including a copy of a parent information sheet. Before any trial-specific
procedures were performed, the parent was asked to sign and date an informed consent form. Following
this, the researcher assessed eligibility and collected baseline clinical and demographic data. Those who
were ineligible were thanked for their time and informed of the reason(s) why they were ineligible.
Randomisation
Researchers at each site entered data from the baseline assessment onto a web-based case report form.
Remote web-based randomisation was undertaken through a fully automated service operated by Uni
Research (Norway) (OpenClinica, version 3.3; Open Clinica, LLC, Waltham, MA, USA). The allocation ratio
for the study was 1 : 1 : 2, such that equal numbers of participants were allocated to IMT and to ESC and,
among those allocated to music therapy, equal numbers were allocated to high- and low-frequency
treatment. Randomisation was stratified by site and made in blocks, with block size randomly assigned
to either four or eight. A project co-ordinator based in Norway (ŁB), who had had no contact with
participants, checked eligibility and baseline data before randomisation via an online system. Following
randomisation, parents and therapists were given information about allocation status, and arrangements
were made for delivering parent advice and support sessions. For those in one of the two experimental
arms of the trial, arrangements were also made for delivering music therapy sessions.
Study researchers were based in separate departments from those involved in organising treatment,
helping to ensure that they remained masked to the allocation status of participants. Parents were given
written information about the importance of researchers not finding out whether or not their child was
receiving music therapy and researchers began every contact with a parent, clinician or teachers with a
reminder of the importance of their remaining masked to the allocation status of the child.
Baseline assessment
At baseline, trained researchers used the ADOS19 and the ADI-R21 to check eligibility. In order to minimise
inconvenience for parents and children, the results of any recent ADOS assessment were used in lieu of
baseline data (so long as this had been completed within 6 weeks prior to their entry into the study). To take
part in the study, potential participants needed to meet the criteria for ASD on the ADOS and on two of the
three domains of the ADI-R. This combination of data from direct observation and interviews with parents
has been used to establish eligibility in previous high-quality trials of interventions for children with ASD.22,23
Researchers also collected baseline data on age and gender of the child and socioeconomic status of the
child’s parent. Finally, researchers collected information about the child’s level of cognitive ability from
medical and school records. When this information was not available, they collected information from the
parent about developmental milestones and presented this to an experienced clinician who used it to
estimate whether the child had no, mild, moderate or severe mental retardation, using the World Health
Organization (International Classification of Diseases, Tenth Edition)’s criteria.24
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Outcome measures
The primary outcome measure was the severity of symptoms of ASD using the social affect algorithm
derived from the ADOS,19,20 assessed by a trained researcher masked to the allocation status of the child.
We selected this measure because of its strong psychometric properties and because it has been widely
used in other RCTs of children with ASD.22,23,25 Higher scores on the ADOS and the social affect algorithm
indicate higher levels of impairment.
The secondary outcome was the Social Responsiveness Scale (SRS)26 – a carer-based assessment of the
severity of ASD symptoms that has high inter-rater and test–retest reliability.27,28
In the NIHR-funded arm of the trial, we added two additional secondary outcomes:
1. Parenting Stress Index – Short Form (PSI-SF): a widely used measure of parental stress that has been
validated among parents of children with ASD. The questionnaire generates three subscores (parental
distress, which indicates the extent to which the respondent is experiencing stress in their role as a
parent; dysfunctional interaction, which indicates the extent to which a parent experiences interactions
with their child as satisfying; and a ‘difficult child’ score, which indicates how easy the respondent finds
it to parent their child). Higher scores on the PSI-SF indicate higher levels of stress.
2. Warwick–Edinburgh Mental Well-Being Scale (WEMWBS): a short validated measure of mental
well-being.29 Higher scores on the WEMWBS indicate higher levels of mental well-being.
All outcome measures were assessed at baseline and at 5 and 12 months.
Interventions
Improvisational music therapy
Improvisational music therapy is a form of music therapy for children with ASD that was originally
developed in Britain in the 1950s by Paul Nordoff and Clive Robbins and was subsequently refined by
Juliette Alvin, and Wigram and Gold.13 It is a child-centred treatment approach that utilises the potential
that making music has to enhance social engagement and the expression of emotions.13 During sessions of
IMT, music played or sung by the therapist generally attunes to the child’s musical or other behaviours,
and aims to engage the child and establish a connection with them. To this end, the ‘musical’ features of
the child’s expression, such as rhythm, melodic patterns and timbre, are expressed through the child
playing tuned and untuned percussion instruments (including wind instruments, such as the recorder and
the kazoo, the keyboard and singing). These musical expressions by the child may be mirrored, reinforced
or complemented by the therapist, who uses the first instrument, such as the keyboard, guitar, clarinet,
flute or other orchestral instrument, thus allowing for moments of synchronisation between the child
and the therapist and giving the child’s expressions a pragmatic meaning within the context of the session.
The therapist uses skills in creating suspense, direction and musical form to draw the child into a musical
relationship. While engaging in joint musical activities, the child is offered adult and child versions of
musical instruments and given opportunities to develop and enhance communication skills through
imitation, joint attention, turn-taking and affect sharing, all of which are associated with development in
language and social competency.30,31
Music therapy sessions in the TIME-A trial lasted for 30 minutes and were delivered over a 5-month period
in local schools or NHS facilities.
All music therapists in the trial had previous experience of working with children with ASD. IMT was
conducted in accordance with a consensus treatment guide of IMT developed for this study16 and the
study protocol.17
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Treatment frequency
The TIME-A trial involved two active treatment groups in which music therapy sessions were offered at two
different levels of frequency: once per week (low frequency) or three times per week (high frequency).
Over the 5-month treatment period, those in the low-frequency treatment arm were offered up to 20
sessions and those in the high-frequency treatment arm were offered up to 60 sessions.
Enhanced standard care
All parents of study participants were offered ESC in addition to usual care from primary and secondary
services; parents were offered three advice and support sessions delivered over a 5-month period. These
sessions were delivered by experienced clinicians who received regular supervision and comprised
psychoeducation, information about support organisations and support in coping with current problems.
This type of support is recommended for parents of children with ASD,10 and helped to ensure that all
study participants received a basic level of support across all study centres.
Treatment fidelity
To determine whether or not treatment was delivered as intended, music therapists were asked to videotape
all sessions. Video recordings were used during monthly supervision sessions, and extracts from a random
sample of recordings were rated by three independent raters across the full international trial, in accordance
with prepublished criteria.16 An average of two independent raters rated 606 randomly selected therapy
sessions on eight main principles of treatment. For each item, scores could range from 0 (not used at all) to
5 (used frequently and with mastery). Scores of ≥ 3 indicated that there was evidence in accordance with the
prepublished criteria.16
Follow-up
Five months after randomisation, parents were contacted by the researcher to make arrangements for their
first follow-up assessment. A parent or teaching assistant was present with the child during assessments.
Follow-up assessments took place at a time that was convenient for the parent and their child. This was
usually at a school or NHS clinic, but occasionally took place in the family’s home. A final follow-up
interview was conducted 12 months after randomisation.
Follow-up assessments were carried out through face-to-face interviews. As well as reimbursing any travel
costs or other reasonable expenses incurred by parents, they were also given a £20 honorarium following
completion of the 12-month follow-up interview.
Sample size
The study had a group sequential design and a planned first interim analysis with around 300 participants
randomised. At a 5% level of statistical significance, and assuming 20% dropout, 300 participants provided
93% power to detect a mean difference of 2.5 on the social affect score of the ADOS at 5 months, but only
20% for a mean difference of 1.0.
At the point when we applied for NIHR funding, 74 children had been recruited to the international trial
and we estimated that it would achieve 200 recruits by the end of the proposed recruitment period.
Therefore, we set out to recruit 100 children to help ensure that the international trial reached its
minimum target of 300 participants.
METHODS
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Data analysis
The main statistical analysis was an intention-to-treat (ITT) analysis of mean change, using longitudinal
models and including all participants who had data of at least one follow-up time point. The primary
analysis compared changes in the social affect score of the ADOS between the two active arms of the trial
and those randomised to ESC at 5 months. We calculated linear mixed-effects models with maximum
likelihood estimation, both unadjusted and adjusted for site as a random effect, and both for the primary
two-arm comparison and for the three-arm comparison, including frequency of IMT. In the sensitivity
analysis for the primary outcome and comparison, we conducted t-tests with multiple imputation for
missing data, imputing 50 data sets and using diagnosis, age and site for the imputation. In a second
sensitivity analysis, we included the music therapist as a random effect nested within site.
As an exploratory analysis, we also analysed the proportion of participants who had any reduction in the
ADOS social affect score, as in a previous study.32 In this binary ITT analysis, we included all participants
randomised improved on the primary outcome, as in a previous study.32 We included all participants
randomised, assuming no improvements for missing data; this was supplemented with an available
case analysis. We calculated risk ratios with two-sided 95% confidence intervals (CIs) using Wald’s
unconditional maximum likelihood estimation. All statistical analyses were conducted using R, version 3.3.1
(The R Foundation for Statistical Computing, Vienna, Austria).33 Differences in parental stress and mental
well-being were compared between the two arms of the trial after adjusting for baseline differences using
linear regression.
Parent involvement
Initial plans for this study were presented at a meeting of 15 parents of children with ASD from Hillingdon
Child Development Centre. Parents supported the overall design of the study, but raised concerns about
how their children would be taken to and from music therapy sessions. They also asked that outcomes
for parents, as well as children, be assessed. Following this feedback, we began to explore options for
delivering music therapy sessions in schools and added two parent-rated outcome measures (the PSI-SF and
the short version of the WEMWBS) to our secondary outcomes.
During the course of the study, we continued to meet parents of children with ASD (four meetings in
London and four between East Anglia and Essex). At these meetings, we updated people on the study
progress and sought their advice on logistical issues. One of the main topics discussed at these meetings
was access to music therapy for children of families who were randomised to the control arm of the trial.
This resulted in an agreement that music therapists would provide workshops for parents at the end of the
study on how they might use music in the interactions with their children.
Parents of children with ASD were also represented on the Project Management Group and the Trial
Steering Committee (TSC). Dr Morag Maskey, who is both a researcher and a parent of a child with ASD,
commented on draft versions of the parent information sheet and a summary of the results of the study,
which was sent to all parents whose children took part in the trial and this report.
Ethics approval and governance
The study was conducted in accordance with the recommendations for physicians involved in research on
human subjects adopted by the 18th World Medical Assembly, Helsinki 1964 and later revisions.34
Ethics approval was obtained by the relevant ethics committees in each of the countries where the study
took place. We obtained approval for the NIHR-funded arm of the study from the National Research Ethics
Service (NRES) Committee West Midlands – The Black Country (Research Ethics Committee reference
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number 14/WM/1047). All parents were provided with written and verbal information about the study
prior to deciding whether or not they and their child would take part. Freely given, written informed
consent was obtained from parents prior to the start of data collection. An independent data monitoring
committee in Norway monitored safety and examined interim efficacy results. In addition, study progress
and safety were reviewed by a separate independent TSC and an independent data monitoring and
ethics committee.
Changes to the study protocol
1. At the start of the study we intended to exclude all those children who had ever received music
therapy. This exclusion was subsequently limited to those who had received music therapy in the
12 months prior to recruitment.
2. In the study protocol we stated that music therapy would not be offered to those in the control arm
of the trial. However, following feedback from parents, some centres provided some music therapy to
children in the control arm of the trial after collection of all 12-month follow-up data had been completed.
3. In the protocol we referred to the primary outcome as ADOS social communication at 5 months.
However, in this report we use the term ‘social affect’ to reflect the algorithm items now used for this
domain of the ADOS.
4. Early in the study it became apparent that delivery of the high-frequency music therapy (three times a
week) would be possible only if children received treatment in school. It was not possible to arrange
transport for children from schools to NHS facilities during the day, and this would also have resulted in
children being taken away from schools. In consultation with teachers and parents, we therefore
arranged for music therapy sessions to be delivered in schools.
5. Feedback from parents attending advisory group meetings in the NIHR study was that, although they
valued the ESC they received, they felt that it was better to describe these sessions as ‘advice and support’
rather than counselling sessions – the name used in the international trial. The name of the sessions was
duly changed. Further details of the methods of the study have been published in Bieleninik et al.18
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Chapter 3 Results
Recruitment to the international study took place between November 2011 and November 2015, andrecruitment to the NIHR-funded arm of the trial was between November 2014 and November 2015.
A total of 702 children were assessed for eligibility in the international trial, of whom 109 were ineligible,
206 declined prior to baseline assessment and another 23 were found ineligible at baseline (Figure 1).
In the NIHR-funded arm of the trial, 103 were assessed for eligibility in the international trial, of whom five
were ineligible and 17 declined prior to baseline assessment (Figure 2).
In the international trial, a total of 364 participants were randomised: 182 to IMT plus ESC, and 182 to
ESC alone. Of the 182 children randomised to receive IMT, 90 were randomised to high-frequency IMT
and 92 to low-frequency IMT.
In the NIHR-funded arm of the trial, 81 participants were randomised, with 41 randomised to IMT (21 high-
frequency and 20 low-frequency treatment). The Norwegian data monitoring committee examined the first
interim efficacy analysis in September 2015. Although the formal criterion for early stopping was not met,
a decision was made to stop further recruitment as a result of the limited funding.
Baseline characteristics were well balanced between study arms, both in the international trial as a whole
(Table 1) and in the sample in the NIHR-funded arm of the study (Table 2). The median age of children in
both the international trial and the NIHR-funded arm was 5.4 years [standard deviation (SD) 0.9 years].
Most children in both the international trial (n = 302, 83.0%) and the NIHR-funded arm of the trial
(n = 67, 82.7%) were male. The proportion with impaired cognitive ability [intelligence quotient (IQ) of
< 70] was higher in the NIHR-funded arm of the study (n = 62, 76.5%) than in the international trial as a
whole (n = 165, 46.3%). Very few children had received music therapy prior to entering the trial (3.4% in
the international trial and 6.2% in the NIHR-funded arm).
A total of 50 participants (14%) in the international trial and nine (11%) in the NIHR-funded arm of the
trial were lost to follow-up at 5 months. The reasons for withdrawal from the study were mainly
attributable to change of address, parental frustration that their child was randomised to ESC or poor
physical health of the child. Baseline characteristics of those who dropped out at 5 months were largely
similar to those who were followed up (Table 3).
Masking of assessors was broken unintentionally in 20 participants (15 in the IMT group and five in the
ESC group). There was no evidence of broken or subverted allocation concealment.
Uptake of interventions
Treatments that children received as part of standard care before and during the study are shown in Table 4.
The most frequent concomitant interventions at baseline were speech and language therapy/communication
training (58%) and sensory/motor therapy (including occupational therapy and physiotherapy; 41%).
These numbers were similar at follow-up (see Table 4). The median number of sessions of all concomitant
interventions (not including parent advice and support or IMT) over the 5-month intervention period was 45 in
those allocated to ESC, compared with 36 in those allocated to IMT (high-frequency IMT, n= 31; low-frequency
IMT, n= 40). Use of concomitant interventions was generally lower among participants recruited at sites funded
by the NIHR, especially regarding behavioural interventions, social skills training and play therapy (Table 5).
The parents of 317 (87%) out of all participants attended at least one session of advice and support; the
median number of sessions was three in all groups. Of those allocated to IMT, 171 (94%) received IMT,
with a median of 34 sessions in those allocated to high-frequency IMT and 15 in those allocated to
low-frequency IMT. Missed sessions were typically because of holidays or illness.
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• Received MT outside
   the study, n = 1 (1%)
• Received IMT
   (median: 34 sessions),
   n = 85 (94%)
• Received ≥ 15 IMT
   sessions, n = 77 (86%)
• Received parent
   advice and support
   (median: three
   sessions), n = 83 (92%)
• Received IMT
   (median: 15 sessions),
   n = 86 (93%)
• Received ≥ 15 IMT
   sessions, n = 57 (62%)
• Received parent
   advice and support
   (median: three
   sessions), n = 83 (90%)
• Received IMT, n = 0
• Received parent
   advice and support
   (median: three
   sessions), n = 151
   (83%)
• Received MT outside
   the study, n = 1 (1%)
• Received MT outside





ADOS, ADI-R, cognitive ability,




Three IMT sessions per week 
(up to 60 sessions), parent advice and 
support (three sessions) and usual care
(n = 90)
Assigned to low-frequency
IMT and ESC 
One IMT session per week 
(up to 20 sessions), parent advice and 
support (three sessions) and usual care
(n = 92)
Assigned to ESC
 Parent advice and support 




• For logistical reasons (66 unable
   to attend required appointments,
   58 too far for ongoing services,
   14 moved out of area), n = 138
• Not interested in participating,
   n = 32
• Unable to contact/did not
   attend, n = 30







• Too old (aged ≥ 7 years), n = 45
• Too young (aged < 4 years), n = 4
• Did not have ASD, n = 26
• Had MT within the last 12 months, 
   n = 30
• Language issues (family), n = 4
• Diagnosis not confirmed
Assessed at 12 months
(n = 72; 80%)
Assessed at 5 months
(n = 78; 87%)
Assessed at 5 months
(n = 87; 95%)
Assessed at 5 months
(n = 149; 82%)
Assessed at 12 months
(n = 82; 89%)
Assessed at 12 months
(n = 136; 75%)
FIGURE 1 Study flow chart for 702 children assessed for the international trial. MT, music therapy.
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• Received MT outside
   the study, n = 0
• Received IMT
   (median: 43 sessions),
   n = 21 (100%)
• Received ≥ 15 IMT
   sessions, n = 21 (100%)
• Received advice and 
   support (median:
   two sessions), n = 21
   (100%)
• Received IMT
   (median: 15 sessions),
   n = 20 (100%)
• Received ≥ 15 IMT
   sessions, n = 15 (75%)
• Received advice and
   support (median:
   two sessions), n = 17
   (85%)
• Received IMT, n = 0
• Received advice and
   support (median: one
   session), n = 30 (75%)
• Received MT outside
   the study, n = 0
• Received MT outside





ADOS, ADI-R, cognitive ability,




Three IMT sessions per week 
(up to 60 sessions), parent advice and




 One IMT session per week 
(up to 20 sessions), parent advice and
 support (three sessions) and usual care
(n = 20)
Assigned to ESC





• For logistical reasons (two unable
   to attend required appointments,
   two moved out of area), n = 4
• Not interested in participating,
   n = 8
• Unable to contact/did not







• Too old (aged ≥ 7 years), n = 2
• Did not have ASD, n = 2
• Had MT within the last 12 months,
   n = 1
• Diagnosis not confirmed
Assessed at 12 months
(n = 18; 86%)
     Assessed at 5 months
(n = 19; 90%)
Assessed at 5 months
(n = 19; 95%)
Assessed at 5 months
(n = 34; 85%)
Assessed at 12 months
(n = 17; 85%)
Assessed at 12 months
(n = 29; 72%)
FIGURE 2 Study flow chart for 103 children assessed for the NIHR-funded arm of the trial. MT, music therapy.
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n Value n Value n Value
Age (years)a 364 5.4 (0.9) 182 5.5 (0.9) 182 5.4 (0.9)
Sex (male)b 364 302 (83%) 182 153 (84.1%) 182 149 (81.9%)
Diagnosisb 364 182 182
Childhood autism (ICD code F84.0) 301 (82.7%) 151 (83%) 150 (82.4%)
Atypical autism (ICD code F84.1) 3 (0.8%) 3 (1.6%) 0 (0%)
Asperger’s syndrome (ICD code F84.5) 14 (3.8%) 8 (4.4%) 6 (3.3%)
PDD (ICD code F84.9)c 46 (12.6%) 20 (11%) 26 (14.3%)
Previous MT (> 12 months ago)b 356 12 (3.4%) 179 4 (2.2%) 177 8 (4.5%)
ADOS moduleb 364 182 182
Module 1 224 (61.5%) 103 (56.6%) 121 (66.5%)
Module 2 129 (35.4%) 73 (40.1%) 56 (30.8%)
Module 3 11 (3%) 6 (3.3%) 5 (2.7%)
ADOS T = totala 363 17.7 (5.3) 182 18 (5.4) 181 17.4 (5.2)
ADOS social affecta 364 13.8 (4.4) 182 14.1 (4.5) 182 13.5 (4.3)
Social responsiveness totala 359 159.5 (28.8) 180 159.3 (27.9) 179 159.7 (29.8)
Concomitant treatmentsa 364 23.7 (28.3) 182 25.5 (31.4) 182 21.9 (24.9)
IQ sourceb 364 182 182
K-ABC 8 (2.2%) 3 (1.6%) 5 (2.7%)
Other standardised test 210 (57.7%) 107 (58.8%) 103 (56.6%)
Clinical judgement 146 (40.1%) 72 (39.6%) 74 (40.7%)
IQ, standardised testa 211 75.4 (26.2) 103 74.7 (25) 108 76.1 (27.4)
Mental retardation (IQ of < 70)b 356 165 (46.3%) 176 81 (46.0%) 180 84 (46.7%)
ADI-R Aa 364 18.3 (5.8) 182 18.4 (5.8) 182 18.2 (5.8)
ADI-R Ba 364 13 (4.2) 182 12.9 (4.1) 182 13.1 (4.3)
ADI-R Ca 364 5.8 (2.4) 182 5.8 (2.3) 182 5.9 (2.5)
ADI-R A, ADI-R reciprocal social interaction; ADI-R B, ADI-R language/communication; ADI-R C, ADI-R repetitive behaviours/
interests; ICD, International Classification of Diseases; K-ABC, Kaufman Assessment Battery for Children; MT, music therapy;
PDD, pervasive developmental disorder.
a Mean (standard deviation).
b n (%).
c Pervasive developmental disorder unspecified.
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In the NIHR-funded arm of the trial, 68 (84.0%) parents offered advice and support attended at least one
session (see Figure 2). The median number of sessions attended was two in the IMT arm of the trial and
one in the ESC arm. All 41 (100%) children randomised to IMT received it. The median number of sessions
attended was 43 in the high-frequency group and 15 in those randomised to the low-frequency group.
Of those allocated to ESC, none received IMT during the 5-month intervention period. However, two
children (1.1%) in each group received music therapy outside the trial before the 12-month follow-up.
Treatment fidelity
Treatment fidelity according to the IMT manual16 was adequate in the vast majority of sessions (Table 6). Two
independent raters agreed that 93% (565/606 randomly selected 3-minute segments from 63 participants)
were conducted adequately (rater 1: 604/606, 99.6%; rater 2: 566/606, 93.4%; results of each principle). The
mean sum score for all eight principles was 26.26 (SD 5.67); a total of 410 sessions (68%) had scores of ≥ 24.










n Value n Value n Value
Age (years)a 81 5.4 (0.9) 41 5.6 (0.9) 40 5.2 (0.9)
Sex (male)b 81 67 (82.7%) 41 33 (80.5%) 40 34 (85%)
Diagnosis [childhood autism (ICD code F84.0)]b 81 81 (100%) 41 41 (100%) 40 40 (100%)
Previous MT (> 12 months ago)b 81 5 (6.2%) 41 2 (4.9%) 40 3 (7.5%)
ADOS moduleb 81 41 40
Module 1 57 (70.4%) 24 (58.5%) 33 (82.5%)
Module 2 24 (29.6%) 16 (39%) 8 (20%)
ADOS totala 81 19.8 (5.8) 41 20.7 (5.8) 40 19 (5.9)
ADOS social affecta 81 15.3 (4.9) 41 15.9 (5.1) 40 14.8 (4.6)
ADOS language and communicationa 81 3.8 (1.6) 41 3.9 (1.7) 40 3.8 (1.5)
ADOS reciprocal social interactiona 81 11.5 (3.9) 41 12 (3.9) 40 11 (3.9)
ADOS restricted and repetitive behavioura 81 4.5 (2.3) 41 4.8 (2.2) 40 4.2 (2.4)
Social responsiveness totala 80 159.1 (28.4) 41 161.5 (28.5) 39 156.5 (28.5)
Concomitant treatmentsa 81 8.3 (14.6) 41 8.3 (15.7) 40 8.2 (13.6)
IQ sourceb 81 41 40
Other standardised test 1 (1.2%) 1 (2.3%) 0 (0%)
Clinical judgement 80 (98.8%) 40 (97.7%) 401 (100%)
Mental retardation (IQ of < 70)b 81 62 (76.5%) 41 28 (68.3%) 40 34 (85%)
ADI-R Aa 81 20.9 (4.8) 41 21.2 (4.4) 40 20.5 (5.1)
ADI-R Ba 81 13.6 (3.5) 41 13.3 (3.4) 40 14 (3.7)
ADI-R Ca 81 5.5 (2.1) 41 5.3 (1.6) 40 5.7 (2.5)
ADI-R A, ADI-R reciprocal social interaction; ADI-R B, ADI-R language/communication; ADI-R C, ADI-R repetitive behaviours/
interests; ICD, International Classification of Diseases; MT, music therapy.
a Mean (standard deviation).
b n (%).
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TABLE 3 Baseline characteristics of those observed vs. those who dropped out at 5 months in the international trial
Characteristics
All
Participants at 5 months
p-value
Followed up Dropped out
n Value n Value n Value
Age (years)a 364 5.4 (0.9) 314 5.4 (0.9) 50 5.3 (0.9) 0.517
Sex (male)b 364 302 (83%) 314 266 (84.7%) 50 36 (72%) 0.044
Diagnosisb 364 314 50 0.645
Childhood autism (ICD code F84.0) 301 (82.7%) 257 (81.8%) 44 (88%)
Atypical autism (ICD code F84.1) 3 (0.8%) 3 (1%) 0 (0%)
Asperger’s syndrome (ICD code F84.5) 14 (3.8%) 12 (3.8%) 2 (4%)
PDD (ICD code F84.9)c 46 (12.6%) 42 (13.4%) 4 (8%)
Previous MT (> 12 months ago)b 356 12 (3.4%) 306 9 (2.9%) 50 3 (6%) 0.491
ADOS moduleb 364 314 50 0.864
Module 1 224 (61.5%) 192 (61.1%) 32 (64%)
Module 2 129 (35.4%) 112 (35.7%) 17 (34%)
Module 3 11 (3%) 10 (3.2%) 1 (2%)
ADOS totala 363 17.7 (5.3) 313 17.6 (5.3) 50 18.1 (5) 0.554
ADOS social affecta 364 13.8 (4.4) 314 13.7 (4.4) 50 14.1 (4.5) 0.569
ADOS LCa,d 364 3.3 (1.5) 314 3.3 (1.5) 50 3.1 (1.4) 0.318
ADOS RSIa,e 364 10.5 (3.6) 314 10.4 (3.5) 50 11 (3.7) 0.285
ADOS RRBa,f 363 3.9 (2) 313 3.9 (2.1) 50 4 (1.6) 0.830
Social responsiveness totala 359 159.5 (28.8) 310 159.1 (28.5) 49 162.3 (31) 0.493
Concomitant treatmentsa 364 23.7 (28.3) 314 23.6 (28.2) 50 24.1 (29.3) 0.919
IQ sourceb 364 314 50 0.161
K-ABC 8 (2.2%) 7 (2.2%) 1 (2%)
Other standardised test 210 (57.7%) 175 (55.7%) 35 (70%)
Clinical judgement 146 (40.1%) 132 (42%) 14 (28%)
IQ, standardised testa 211 75.4 (26.2) 178 75.9 (26.3) 33 72.8 (25.7) 0.539
Mental retardation, (IQ of < 70)b 356 165 (46.3%) 309 144 (46.6%) 47 21 (44.7%) 0.929
ADI-R Aa 364 18.3 (5.8) 314 18.2 (5.8) 50 18.6 (5.5) 0.698
ADI-R Ba 364 13 (4.2) 314 13.1 (4.2) 50 12.6 (3.9) 0.453
ADI-R Ca 364 5.8 (2.4) 314 5.9 (2.5) 50 5.3 (1.9) 0.032
ADI-R A, ADI-R reciprocal social interaction; ADI-R B, ADI-R language/communication; ADI-R C, ADI-R repetitive behaviours/
interests; ICD, International Classification of Diseases; K-ABC, Kaufman Assessment Battery for Children; MT, music therapy;
PDD, pervasive developmental disorder.
a Mean (SD), p-value for t-test.
b n (%), p-value for chi-squared test.
c Pervasive developmental disorder unspecified.
d Language and communication.
e Reciprocal social interaction.
f Restricted and repetitive behaviour.
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TABLE 4 Use of concomitant treatments among 364 participants in the international trial
Intervention
Time point, n (%)
Baseline 5 months 12 months
Sensory/motor therapy (including occupational therapy and physiotherapy) 151 (41) 109 (34) 104 (35)
Speech and language therapy and communication training 210 (58) 163 (52) 155 (52)
Play therapy or DIR/floor-time approach 35 (10) 28 (9) 18 (6)
Behavioural/educational intervention (e.g. TEACCH or ABA) 55 (15) 45 (14) 48 (16)
Social skills training 31 (9) 43 (14) 46 (15)
Therapeutic leisure activities (e.g. horse riding) 47 (13) 55 (17) 49 (16)
Other interventions 60 (16) 63 (20) 67 (23)
No specific therapy or intervention (outside this study) 55 (15) 45 (14) 37 (12)
Institutional stay 12 (3) 9 (3) 8 (3)
Outpatient treatment 38 (10) 19 (6) 25 (8)
Supplement or medication 110 (30) 74 (23) 75 (25)
Special diet 61 (17) 32 (10) 31 (10)
ABA, Applied Behaviour Analysis; DIR, developmental, individual differences and relationship-based model; TEACCH,
Treatment and Education of Autistic and Communication Handicapped Children.
Notes
Time point: n= 364 (baseline), n= 316 (5 months), n= 297 (12 months).
At each time point, parents were asked to report interventions received during the past 2 months.
TABLE 5 Use of concomitant treatments among 81 participants in the NIHR-funded recruitment sites
Intervention
Time point, n (%)
Baseline 5 months 12 months
Sensory/motor therapy (including occupational therapy and physiotherapy) 27 (33) 10 (14) 16 (25)
Speech and language therapy and communication training 46 (57) 26 (36) 32 (50)
Play therapy or DIR/floor-time approach 3 (4) 2 (3) 1 (2)
Behavioural/educational intervention (e.g. TEACCH or ABA) 1 (1) 2 (3) 4 (6)
Social skills training 1 (1) 3 (4) 6 (9)
Therapeutic leisure activities (e.g. horse riding) 3 (4) 3 (4) 6 (9)
Other interventions 6 (7) 8 (11) 9 (14)
No specific therapy or intervention (outside this study) 14 (17) 8 (11) 7 (11)
Institutional stay 2 (2) 1 (1) 2 (3)
Outpatient treatment 15 (19) 6 (8) 8 (12)
Supplement or medication 35 (43) 12 (17) 13 (20)
Special diet 25 (31) 9 (12) 8 (12)
ABA, Applied Behaviour Analysis; DIR, developmental, individual differences and relationship-based model; TEACCH,
Treatment and Education of Autistic and Communication Handicapped Children.
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Primary outcome and secondary outcomes in the international trial
From baseline to 5 months, mean scores of ADOS social affect decreased from 14.1 to 13.3 in the music
therapy group and from 13.5 to 12.4 in standard care. Unadjusted linear mixed-effects models indicate
that the mean change from baseline in the ADOS social affect score at 5 months was similar among those
randomised to IMT and to ESC (mean difference 0.06, 95% CI –0.70 to 0.81; p = 0.88) (Table 7). The
models adjusted for site showed similar results (Table 8). Although improvements in social affect were seen
at 5 and 12 months for the group as a whole, differences in mean score on the ADOS social affect scale
between those randomised to IMT and to ESC were not statistically significant. From baseline to 5 months,
the parent-rated social responsiveness score decreased from 96.0 to 89.2 in music therapy and from 96.1
to 93.3 in standard therapy, with no significant difference in improvement (mean difference, music therapy
vs. standard care = –3.39, 95% CI –7.56 to 0.91; p = 0.13).
TABLE 6 Mean fidelity scores of 606 therapy sessions in accordance with IMT principles
IMT principle Mean fidelity score (SD) Frequently used, number of sessions (%)
Musical and emotional attunement 3.45 (0.74) 495 (82)
Scaffolding interaction musically 3.16 (0.79) 426 (70)
Tapping into shared musical history 2.98 (0.93) 363 (60)
Positive therapeutic relationship 3.67 (0.78) 529 (87)
Secure environment 3.7 (0.71) 548 (91)
Following the child’s lead 3.08 (0.87) 408 (67)
Treatment goals 3.24 (0.76) 454 (75)
Enjoyment of interaction 2.97 (0.92) 372 (61)
TABLE 7 Mean scores on primary outcome (ADOS social affect scale) and secondary outcomes among 364
participants in the international trial
Outcome
Observed values Change from baseline
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a Larger negative numbers in these columns indicate greater improvements in functioning.
b Wald’s test for different change in the groups from baseline.
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No differences were seen in ADOS social affect score at 5 or 12 months between those randomised to
high- and low-frequency IMT or between those randomised to IMT and ESC at 12 months (Table 9).
Statistically significant differences were also not found for total score on the SRS between those
randomised to music therapy or ESC at either 5 or 12 months (Tables 10 and 11) nor in subscales of the
ADOS or the SRS (see Appendix 1).
TABLE 8 Linear mixed-effects analyses for ADOS social affect score among 364 participants in the
international trial
ADOS social affect score
Analysis
Unadjusted Adjusted for site
β SE df t p-value β SE df t p-value
Intercept 13.49 0.34 868 39.2 0.000 13.67 0.58 868 23.4 0.000
Group (IMT) 0.59 0.49 362 1.2 0.227 0.45 0.46 352 1.0 0.324
5 months vs. baseline –0.91 0.28 868 –3.2 0.001 –0.90 0.28 868 –3.2 0.001
12 months vs. baseline –1.63 0.29 868 –5.7 0.000 –1.62 0.29 868 –5.6 0.000
Group × (5 months vs. baseline) 0.06 0.39 868 0.2 0.882 0.05 0.39 868 0.1 0.900
Group × (12 months vs. baseline) 0.16 0.40 868 0.4 0.692 0.14 0.40 868 0.4 0.729
df, degrees of freedom; SE, standard error.
Negative values indicate improvements in social and communication skills.
TABLE 9 Linear mixed-effects analyses for ADOS social affect score among those randomised to high- or
low-frequency music therapy and ESC
ADOS social affect score
Analysis
Unadjusted Adjusted for site
β SE df t p-value β SE df t p-value
Intercept 13.49 0.34 865 39.2 0.000 13.68 0.59 865 23.3 0.000
IMT-HI (three per week) vs. ESC 0.91 0.60 361 1.5 0.129 0.86 0.57 351 1.5 0.130
IMT-LO (one per week) vs. ESC 0.27 0.59 361 0.5 0.647 0.06 0.56 351 0.1 0.920
5 months vs. baseline –0.91 0.28 865 –3.2 0.001 –0.90 0.28 865 –3.2 0.001
12 months vs. baseline –1.63 0.29 865 –5.7 0.000 –1.62 0.29 865 –5.6 0.000
[IMT-HI (three per week) vs.
ESC] × (5 months vs. baseline)
–0.24 0.48 865 –0.5 0.610 –0.26 0.48 865 –0.5 0.593
[IMT-LO (one per week) vs.
ESC] × (5 months vs. baseline)
0.34 0.46 865 0.7 0.470 0.33 0.46 865 0.7 0.475
[IMT-HI (three per week) vs.
ESC] × (12 months vs. baseline)
0.18 0.49 865 0.4 0.715 0.16 0.49 865 0.3 0.751
[IMT-LO (one per week) vs.
ESC] × (12 months vs. baseline)
0.15 0.48 865 0.3 0.758 0.13 0.48 865 0.3 0.780
df, degrees of freedom; HI, high frequency; LO, low frequency; SE, standard error.
Negative values indicate improvements in social and communication skills.
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Adverse events, hospitalisation or other institutional stays were rare at baseline (three in those randomised
to ESC and nine in those randomised to IMT). During the study, there were three admissions to hospital in
the ESC arm of the trial at 5 months and four at 12 months. In the IMT arm of the trial, there were six
admissions to hospital at 5 months and four at 12 months. These institutional stays were typically short
admissions for planned treatment of coexisting physical health conditions unrelated to the study. No other
adverse events were reported.





Unadjusted Adjusted for site
β SE df t p-value β SE df t p-value
Intercept 159.45 2.17 776 73.5 0.000 159.21 3.46 776 46.0 0.000
Group (IMT) –0.37 3.06 361 –0.1 0.904 –0.71 2.89 351 –0.3 0.806
5 months vs. baseline –1.53 1.60 776 –1.0 0.338 –1.29 1.60 776 –0.8 0.421
12 months vs. baseline –4.17 1.61 776 –2.6 0.010 –3.92 1.61 776 –2.4 0.015
Group × (5 months vs. baseline) –3.39 2.21 776 –1.5 0.126 –3.64 2.21 776 –1.7 0.100
Group × (12 months vs. baseline) –2.53 2.25 776 –1.1 0.262 –2.74 2.25 776 –1.2 0.223
df, degrees of freedom; SE, standard error.
TABLE 11 Linear mixed-effects analyses for total score on the SRS among those randomised to high- or
low-frequency music therapy and ESC
SRS total score
Analysis
Unadjusted Adjusted for site
β SE df t p-value β SE df t p-value
Intercept 159.45 2.17 773 73.4 0.000 159.21 3.47 773 45.9 0.000
IMT-HI (three per week) vs. ESC –0.74 3.77 360 –0.2 0.844 –1.09 3.56 350 –0.3 0.760
IMT-LO (one per week) vs. ESC –0.01 3.74 360 0.0 0.997 –0.34 3.54 350 –0.1 0.923
5 months vs. baseline –1.53 1.60 773 –1.0 0.338 –1.29 1.60 773 –0.8 0.422
12 months vs. baseline –4.17 1.62 773 –2.6 0.010 –3.92 1.61 773 –2.4 0.015
[IMT-HI (three per week) vs.
ESC] × (5 months vs. baseline)
–4.60 2.77 773 –1.7 0.097 –4.88 2.76 773 –1.8 0.077
[IMT-LO (one per week) vs.
ESC] × (5 months vs. baseline)
–2.45 2.63 773 –0.9 0.352 –2.68 2.63 773 –1.0 0.308
[IMT-HI (three per week) vs.
ESC] × (12 months vs. baseline)
–1.41 2.81 773 –0.5 0.615 –1.67 2.80 773 –0.6 0.550
[IMT-LO one per week) vs.
ESC] × (12 months vs. baseline)
–3.49 2.69 773 –1.3 0.195 –3.68 2.69 773 –1.4 0.172
df, degrees of freedom; HI, high frequency; LO, low frequency; SE, standard error.
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Response rates on the Autism Diagnostic Observation Schedule social
affect scale at five months
Exploratory analyses in the ITT population indicated a 25% higher proportion of improved cases in ADOS
social affect score at 5 months in the IMT arm (95/182, 52%) than in the ESC arm (76/182, 42%) (risk
ratio 1.25, 95% CI 1.00 to 1.56; p = 0.046). These results were similar in available case analyses and in
analyses by dose group (Table 12). Subgroup analyses (Figure 3) suggested greater positive differences in
response for some clinical groups, including male participants (p = 0.040), those with childhood autism
(p = 0.025) or a low IQ (p = 0.049) and those who received at least 15 IMT sessions (risk ratio 1.39,
95% CI 1.11 to 1.74; p = 0.004).
Outcomes among people recruited in the National Institute for Health
Research-funded arm of the study
The NIHR-funded arm of the trial was not sufficiently powered to detect statistically significant differences
in outcomes and we did not find significant differences in ADOS social affect score (Tables 13 and 14) or
social responsiveness (Table 15) between those randomised to music therapy and ESC or between those
randomised to high- or low-frequency music therapy compared with those randomised to ESC in the
NIHR-funded arm of the trial. Nor were differences found in subscales of the ADOS or SRS (see Appendix 2).
A number of parents did not provide data on mental well-being and levels of stress, with only 40 (49.4%)
providing data at 5 months and 43 (53.1%) providing data at 12 months. Differences in total scores and
subscales of the PSI-SF at 5 and 12 months are presented in Table 16. Differences in levels of parental
distress at 12 months were significantly lower among parents of children randomised to music therapy.
TABLE 12 Response rates at 5 months on ADOS social affect score among those randomised to high- or




High-frequency IMT 51% (46/90) 59% (46/78)
Low-frequency IMT 53% (49/92) 56% (49/87)
Any IMT 52% (95/182) 58% (95/165)
ESC 42% (76/182) 51% (76/149)
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1.34 (1.04 to 1.74)
0.97 (0.65 to 1.45)
1.20 (0.93 to 1.55)
1.45 (0.95 to 2.22)
1.35 (0.96 to 1.88)
1.15 (0.86 to 1.54)
1.43 (1.00 to 2.05)
1.17 (0.89 to 1.54)
1.46 (0.93 to 2.32)
1.19 (0.93 to 1.53)
1.17 (0.93 to 1.48)
1.74 (0.95 to 3.17)
1.39 (1.11 to 1.74)
1.25 (1.00 to 1.56)













TABLE 13 Mean scores on primary outcome (ADOS social affect scale) and secondary outcomes among
81 participants in the NIHR-funded arm of the trial
Outcome
Observed values Change from baseline


























































a Larger negative numbers in these columns indicate greater improvements in functioning.
b Wald’s test for different change in the groups from baseline.
TABLE 14 Linear mixed-effects analyses for ADOS social affect score among 81 participants in the NIHR-funded arm
of the trial
ADOS social affect score
Analysis
Unadjusted Adjusted for site
β SE df t p-value β SE df t p-value
Intercept 14.83 0.80 152 18.4 0.000 15.13 1.25 152 12.1 0.000
Group (IMT) 1.03 1.13 79 0.9 0.365 0.87 1.09 78 0.8 0.426
5 months vs. baseline –0.66 0.68 152 –1.0 0.333 –0.70 0.68 152 –1.0 0.304
12 months vs. baseline –1.32 0.72 152 –1.8 0.070 –1.35 0.72 152 –1.9 0.063
Group × (5 months vs. baseline) –0.73 0.94 152 –0.8 0.440 –0.70 0.94 152 –0.7 0.458
Group × (12 months vs. baseline) –0.68 0.99 152 –0.7 0.490 –0.65 0.99 152 –0.7 0.508
df, degrees of freedom; SE, standard error.
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TABLE 15 Linear mixed-effects analyses for social responsiveness score among 81 participants in the NIHR-funded arm of the trial
Social responsiveness total score
Analysis
Unadjusted Adjusted for site
β SE df t p-value β SE df t p-value
Intercept 95.14 4.12 90 23.1 0.000 95.14 4.12 90 23.1 0.000
Group (IMT) 6.71 5.77 79 1.2 0.249 6.71 5.77 78 1.2 0.249
5 months vs. baseline 10.01 4.28 90 2.3 0.021 10.01 4.28 90 2.3 0.021
12 months vs. baseline 4.02 4.08 90 1.0 0.327 4.02 4.08 90 1.0 0.327
Group × (5 months vs. baseline) –8.02 6.02 90 –1.3 0.186 –8.02 6.02 90 –1.3 0.186
Group × (12 months vs. baseline) –0.22 5.81 90 0.0 0.970 –0.22 5.81 90 0.0 0.970
df, degrees of freedom; SE, standard error.
TABLE 16 Parental stress and mental well-being reported by parents of children in the NIHR-funded arm of the trial
Outcome
Treatment arm, mean score (SD) Difference at


















































a Higher scores indicate higher levels of parental distress.














The results of this international multicentre trial do not provide good evidence that IMT delivered over5 months leads to changes in social affect or social responsiveness in children aged 4–7 years with ASD.
Children across the study centres engaged well with the music therapy and we did not find evidence of
harms. Secondary analysis of data found that the proportion of children who had some improvement in
social affect were, to a greater extent, among those randomised to IMT and among subgroups of those
offered music therapy, including males, those with childhood autism, those with coexisting intellectual
disability and those who received more than 15 sessions of therapy.
Results of the study among children who were recruited to the trial at NIHR-funded centres were similar
to those in other international centres with high rates of uptake, and there were no statistically significant
differences in study outcomes. Data from parents of children in the NIHR-funded arm of the study
suggested that levels of stress were lower at 12 months among parents of children who were offered
music therapy.
Strengths and weaknesses of the study design
The TIME-A study is the first large-scale trial of music therapy for children with ASD and also the largest
trial of any intervention for children with ASD completed to date. The study tested the effects of the
intervention in a broad range of different countries and settings and used validated measures of social
affect and responsiveness that are at the core of the difficulties experienced by children with ASD. Other
strengths of the study were that the efforts to maintain masking of study researchers were largely
successful and there was a limited number of missing data, which was achieved by successfully following
up 87% of children at 5 months.
One of the main weaknesses of the study was the limited selection of outcome measures that we used.
At the time that the study was designed, there was a lack of validated measures of the core problems of
social affect and communication experienced by children with ASD that were sensitive to change.35,36 The
ADOS was originally developed as a diagnostic tool to assess whether or not children have impairments
and unusual behaviours that would indicate ASD. Although some previous studies have used the ADOS to
assess the clinical effectiveness of interventions,22,37,38 concerns have been raised about the suitability of the
ADOS to assess changes in the adaptive functioning of children with ASD.39 Similar limitations apply to the
SRS as an outcome measure for measurement of skill development in young children. A systematic review
of outcome measures used to assess the impact of interventions for young children with ASD concluded
that there is an urgent need for validated assessments that are sensitive to change.35 Following this, the
Brief Observation of Social Communication Change was developed specifically to assess changes in social
communication skills of children with ASD.40 Longitudinal data from children with ASD suggest that the
Brief Observation of Social Communication Change may be more sensitive to change than the ADOS,40
and we cannot rule out the possibility that music therapy brought about changes in social affect that were
not detected using the ADOS.
The international trial group deliberately restricted the number of outcome measures used to reduce the
burden of follow-up assessments for children and their parents. Feedback from some parents of children
who received music therapy suggested that potential future parent-reported outcomes may include broader
improvements, such as the child’s functioning or anxiety, and those that we did not assess in this study.
Although the study was sufficiently powered to detect clinically important effects, it was not large enough
to detect small differences in social affect and responsiveness that may still be valued by children and their
families. The results of our secondary analysis of response rates provide some evidence that such changes
may be associated with the intervention tested in this trial.
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Although children in the study were followed up for longer than in any previous study of music therapy for
children with ASD, the final follow-up was 12 months after randomisation. Recent findings from a trial of
parent-mediated communication-focused therapy failed to find clear evidence of effectiveness at 1 year,22
but did so at 5 years.37 We cannot rule out the possibility that there could have been differences in
outcomes for children over a longer period. However, a further difference from that study is that the
involvement of parents allows for generalisation across situations, and the music therapy as delivered in
this trial did not consistently involve parents in a way that transferred skills.
Finally, although the rate of follow-up in the study was high, only half of the parents in the NIHR-funded
arm of the trial completed the assessment of stress and mental well-being. We believe that this resulted
from asking parents to complete and return these measures at their convenience rather than integrating
them into the main, face-to-face assessment.
The National Institute for Health Research-funded arm of the trial
The NIHR-funded arm of the trial aimed to help ensure that the international study achieved its minimum
recruitment target of 300 children and families, and to assess whether or not the outcomes of the trial
were similar in England compared with other centres. At the point at which recruitment to the
international trial ceased (on 1 November 2015), we had randomised 81 out of the 100 children and
families we set out to recruit. The NIHR-funded arm of the trial is the largest of any of the arms of the
study and successfully helped to ensure that the minimum recruitment target was reached.
Feedback from parents who attended the project advisory group was that it would be difficult to make
arrangements for children to attend a treatment that might be delivered three times per week unless it
was integrated into the school day. This led us to make arrangements to deliver most music therapy
sessions in specialist schools working with children with ASD and other special needs. When music therapy
sessions were delivered at the child’s school, attendance rates were high and we believe that is the main
reason why levels of attendance among those allocated to high-frequency treatment were higher in the
NIHR-funded arm of the trial (median n = 43) than at other study centres (median n = 34) where treatment
was usually delivered in clinics. In contrast, attendance at parent advice and support sessions was lower in
the NIHR-funded arm of the trial than at other centres. This may be because these sessions were generally
organised at NHS clinics rather than at the child’s school.
In terms of demographic and clinical characteristics, children recruited to the study in the NIHR-funded arm
of the trial were broadly similar to those recruited at other centres, with the exception of levels of coexisting
intellectual disability. Although less than half (46.3%) of the children in the trial as a whole were judged to
have coexisting intellectual disability, 62 out of the 81 children (76.5%) recruited in the NIHR-funded arm
of the trial were judged to have an IQ of < 70. We believe that this resulted from our focus on recruiting
children who were attending specialist schools.
With regard to outcomes of music therapy, we did not find evidence of differences in social affect or social
responsiveness among children randomised to music therapy or ESC in either the international trial or the
NIHR-funded arm of the study.
Our ability to assess whether or not the parents of children randomised to music therapy experienced
different levels of stress or mental well-being in the following year was limited by the poor follow-up rate.
However, the data we were able to collect showed that it is possible that IMT for children with ASD was
associated with lower levels of parental distress and we believe that this is an area that merits further
examination in future studies.
DISCUSSION
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Comparison with results of previous trials
In contrast with the results of the TIME-A study, previous trials of music therapy for children with ASD have
reported improvements in social affect and communication;12 however, the methodological quality of
previous trials has been moderate or low and, in some, researchers were not masked to allocation status.
Previous studies have also tended to focus on outcomes assessed within therapy. A methodological
strength of the TIME-A study is that it assessed whether or not any such effects could be seen outside of
therapy sessions and with an unfamiliar adult. The relative absence of information about the generalised
effects of music therapy was highlighted in a previous systematic review,12 and the results of this trial
directly address whether or not changes that appear to take place during therapy sessions can be seen
outside the treatment context.
Implications for services and future research
We did not find clear evidence that individual IMT improves social affect and social responsiveness of
children with ASD aged 4–7 years, as tested in this trial. However, our finding that music therapy may be
more likely to influence social affect of children with childhood autism (as opposed to other ASD) and
those with coexisting intellectual disability suggests that further assessment of the role of IMT in treating
these children is warranted. Such research should include validated measures of social communication
that are more sensitive to change, such as the Brief Observation of Social Communication Change.40
Following feedback from parents about their experience of seeing changes in broader aspects of child
mental health, such as anxiety, we believe that such studies should also include these important aspects of
mental health. Assessing the impact of interventions for children with autism on anxiety is particularly
important given the associations between anxiety and social functioning.41
Feedback from parents who took part in the TIME-A study was that they valued contact with music therapists
in order to get a better understanding of the intervention and how they might use music to try to enhance
their communication with their children.42 In recent years, parent- and family-centred approaches to music
therapy have begun to be developed.43 This approach involves music therapists working with parents and
other family members, to support the whole family and try to embed a positive therapeutic culture in the
family dynamic. Such an approach also has the potential to increase the exposure of children to music-based
interventions beyond that which can be achieved in traditional music therapy sessions. A recent pilot RCT of
family-centred music therapy found evidence of increased social interaction, and this approach to delivering
music therapy to children with ASD44 is worthy of further investigation.
Conclusions
Adding IMT to services received by children with ASD in this trial did not result in improvements in social
affect or responsiveness.
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Appendix 1 Linear mixed-effects analyses:
secondary outcomes at 5 and 12 months among
364 participants in the international trial
Outcome
Analysis
Unadjusted Adjusted for site
β SE df t p-value β SE df t p-value
ADOS total score
Intercept 17.37 0.42 865 41.7 0.000 17.43 0.60 865 29.3 0.000
Group (IMT) 0.65 0.59 361 1.1 0.273 0.54 0.57 351 1.0 0.342
5 months vs. baseline –1.08 0.32 865 –3.4 0.001 –1.07 0.32 865 –3.4 0.001
12 months vs. baseline –2.03 0.33 865 –6.2 0.000 –2.01 0.33 865 –6.1 0.000
Group × (5 months vs. baseline) 0.11 0.44 865 0.2 0.807 0.10 0.44 865 0.2 0.825
Group × (12 months vs. baseline) 0.33 0.45 865 0.7 0.461 0.31 0.45 865 0.7 0.488
ADOS social affect score
Intercept 13.49 0.34 868 39.2 0.000 13.67 0.58 868 23.4 0.000
Group (IMT) 0.59 0.49 362 1.2 0.227 0.45 0.46 352 1.0 0.324
5 months vs. baseline –0.91 0.28 868 –3.2 0.001 –0.90 0.28 868 –3.2 0.001
12 months vs. baseline –1.63 0.29 868 –5.7 0.000 –1.62 0.29 868 –5.6 0.000
Group × (5 months vs. baseline) 0.06 0.39 868 0.2 0.882 0.05 0.39 868 0.1 0.900
Group × (12 months vs. baseline) 0.16 0.40 868 0.4 0.692 0.14 0.40 868 0.4 0.729
ADOS language and communication score
Intercept 3.25 0.12 869 28.1 0.000 3.31 0.24 869 13.8 0.000
Group (MT) 0.10 0.16 362 0.6 0.524 0.05 0.15 352 0.3 0.746
5 months vs. baseline –0.40 0.11 869 –3.7 0.000 –0.39 0.11 869 –3.5 0.000
12 months vs. baseline –0.54 0.11 869 –4.8 0.000 –0.52 0.11 869 –4.6 0.000
Group × (5 months vs. baseline) 0.13 0.15 869 0.8 0.411 0.11 0.15 869 0.7 0.486
Group × (12 months vs. baseline) 0.16 0.16 869 1.0 0.297 0.13 0.16 869 0.9 0.393
ADOS reciprocal social interaction score
Intercept 10.24 0.28 868 37.1 0.000 10.34 0.39 868 26.8 0.000
Group (IMT) 0.48 0.39 362 1.2 0.216 0.41 0.38 352 1.1 0.277
5 months vs. baseline –0.50 0.23 868 –2.2 0.030 –0.50 0.23 868 –2.2 0.030
12 months vs. baseline –1.09 0.24 868 –4.6 0.000 –1.09 0.24 868 –4.6 0.000
Group × (5 months vs. baseline) –0.06 0.32 868 –0.2 0.840 –0.07 0.32 868 –0.2 0.838
Group × (12 months vs. baseline) –0.01 0.33 868 0.0 0.978 –0.02 0.33 868 –0.1 0.961
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Unadjusted Adjusted for site
β SE df t p-value β SE df t p-value
ADOS restricted and repetitive behaviour score
Intercept 3.91 0.15 866 26.4 0.000 3.77 0.26 866 14.4 0.000
Group (IMT) 0.03 0.21 361 0.2 0.873 0.06 0.20 351 0.3 0.762
5 months vs. baseline –0.21 0.14 866 –1.5 0.139 –0.20 0.14 866 –1.4 0.151
12 months vs. baseline –0.48 0.14 866 –3.3 0.001 –0.47 0.14 866 –3.2 0.001
Group × (5 months vs. baseline) 0.08 0.19 866 0.4 0.665 0.08 0.19 866 0.4 0.675
Group × (12 months vs. baseline) 0.26 0.20 866 1.3 0.194 0.25 0.20 866 1.3 0.203
SRS total score
Intercept 159.45 2.17 776 73.5 0.000 159.21 3.46 776 46.0 0.000
Group (IMT) –0.37 3.06 361 –0.1 0.904 –0.71 2.89 351 –0.3 0.806
5 months vs. baseline –1.53 1.60 776 –1.0 0.338 –1.29 1.60 776 –0.8 0.421
12 months vs. baseline –4.17 1.61 776 –2.6 0.010 –3.92 1.61 776 –2.4 0.015
Group × (5 months vs. baseline) –3.39 2.21 776 –1.5 0.126 –3.64 2.21 776 –1.7 0.100
Group × (12 months vs. baseline) –2.53 2.25 776 –1.1 0.262 –2.74 2.25 776 –1.2 0.223
SRS awareness score
Intercept 20.25 0.31 789 65.4 0.000 20.29 0.49 789 41.0 0.000
Group (IMT) –0.39 0.44 361 –0.9 0.371 –0.47 0.41 351 –1.1 0.256
5 months vs. baseline –0.18 0.28 789 –0.7 0.515 –0.12 0.28 789 –0.4 0.668
12 months vs. baseline –0.56 0.28 789 –2.0 0.043 –0.51 0.28 789 –1.8 0.070
Group × (5 months vs. baseline) –0.14 0.38 789 –0.4 0.713 –0.19 0.38 789 –0.5 0.616
Group × (12 months vs. baseline) 0.28 0.39 789 0.7 0.473 0.24 0.39 789 0.6 0.533
SRS cognition score
Intercept 30.15 0.47 789 64.7 0.000 30.06 0.65 789 46.4 0.000
Group (IMT) –0.60 0.66 362 –0.9 0.364 –0.63 0.64 352 –1.0 0.329
5 months vs. baseline –0.38 0.42 789 –0.9 0.365 –0.33 0.42 789 –0.8 0.428
12 months vs. baseline –1.05 0.42 789 –2.5 0.013 –0.99 0.42 789 –2.4 0.018
Group × (5 months vs. baseline) –0.48 0.58 789 –0.8 0.409 –0.52 0.58 789 –0.9 0.365
Group × (12 months vs. baseline) 0.07 0.59 789 0.1 0.909 0.03 0.59 789 0.1 0.964
SRS communication score
Intercept 53.49 0.80 789 67.0 0.000 53.33 1.09 789 48.9 0.000
Group (IMT) –0.22 1.13 362 –0.2 0.846 –0.28 1.10 352 –0.3 0.795
5 months vs. baseline –1.07 0.71 789 –1.5 0.129 –0.99 0.71 789 –1.4 0.162
12 months vs. baseline –1.97 0.71 789 –2.8 0.006 –1.88 0.71 789 –2.7 0.008
Group × (5 months vs. baseline) –1.32 0.98 789 –1.4 0.178 –1.41 0.98 789 –1.5 0.149
Group × (12 months vs. baseline) –0.32 0.99 789 –0.3 0.748 –0.41 0.99 789 –0.4 0.682
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Unadjusted Adjusted for site
β SE df t p-value β SE df t p-value
SRS motivation score
Intercept 25.93 0.43 789 61.0 0.000 25.96 0.63 789 41.4 0.000
Group (IMT) –0.23 0.60 362 –0.4 0.702 –0.32 0.58 352 –0.5 0.586
5 months vs. baseline –0.65 0.38 789 –1.7 0.088 –0.60 0.38 789 –1.6 0.115
12 months vs. baseline –1.02 0.38 789 –2.7 0.008 –0.98 0.38 789 –2.6 0.011
Group × (5 months vs. baseline) –0.99 0.53 789 –1.9 0.060 –1.03 0.53 789 –2.0 0.051
Group × (12 months vs. baseline) –0.79 0.54 789 –1.5 0.139 –0.82 0.54 789 –1.5 0.127
SRS mannerisms score
Intercept 29.34 0.54 788 54.8 0.000 29.39 0.82 788 35.7 0.000
Group (IMT) 0.82 0.76 362 1.1 0.281 0.76 0.72 352 1.1 0.293
5 months vs. baseline 0.19 0.44 788 0.4 0.674 0.25 0.44 788 0.6 0.573
12 months vs. baseline –0.15 0.45 788 –0.3 0.743 –0.08 0.45 788 –0.2 0.860
Group × (5 months vs. baseline) –1.20 0.62 788 –2.0 0.052 –1.27 0.61 788 –2.1 0.039
Group × (12 months vs. baseline) –1.14 0.63 788 –1.8 0.068 –1.21 0.63 788 –1.9 0.054
df, degrees of freedom; SE, standard error.
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Appendix 2 Linear mixed-effects analyses:
secondary outcomes at 5 and 12 months among
81 participants in the NIHR-funded arm of the trial
Outcome
Analyses
Unadjusted Adjusted for site
β SE df t p-value β SE df t p-value
ADOS language and communication score
Intercept 3.80 0.26 153 14.8 0.000 3.95 0.51 153 7.7 0.000
Group (IMT) 0.08 0.36 79 0.2 0.830 0.00 0.33 78 0.0 0.998
5 months vs. baseline –0.49 0.22 153 –2.2 0.029 –0.51 0.22 153 –2.3 0.024
12 months vs. baseline –0.63 0.24 153 –2.7 0.009 –0.63 0.23 153 –2.7 0.008
Group × (5 months vs. baseline) 0.28 0.31 153 0.9 0.368 0.29 0.31 153 0.9 0.347
Group × (12 months vs. baseline) 0.20 0.32 153 0.6 0.535 0.20 0.32 153 0.6 0.526
ADOS reciprocal social interaction score
Intercept 11.02 0.66 152 16.8 0.000 11.14 0.80 152 14.0 0.000
Group (IMT) 0.95 0.92 79 1.0 0.307 0.89 0.91 78 1.0 0.333
5 months vs. baseline –0.16 0.61 152 –0.3 0.794 –0.18 0.61 152 –0.3 0.767
12 months vs. baseline –0.69 0.65 152 –1.1 0.285 –0.71 0.65 152 –1.1 0.274
Group × (5 months vs. baseline) –1.04 0.84 152 –1.2 0.220 –1.02 0.84 152 –1.2 0.228
Group × (12 months vs. baseline) –0.92 0.88 152 –1.1 0.295 –0.91 0.88 152 –1.0 0.303
ADOS restricted and repetitive behaviour score
Intercept 4.19 0.33 153 12.5 .000 4.18 0.34 153 12.2 0.000
Group (IMT) 0.62 0.47 79 1.3 .193 0.62 0.47 78 1.3 0.190
5 months vs. baseline –0.18 0.29 153 –0.6 .531 –0.18 0.29 153 –0.6 0.534
12 months vs. baseline –0.39 0.31 153 –1.3 .211 –0.39 0.31 153 –1.3 0.212
Group × (5 months vs. baseline) –0.35 0.40 153 –0.9 .380 –0.35 0.40 153 –0.9 0.379
Group × (12 months vs. baseline) –0.53 0.42 153 –1.3 .210 –0.53 0.42 153 –1.3 0.209
SRS total score
Intercept 95.14 4.12 90 23.1 0.000 95.14 4.12 90 23.1 0.000
Group (IMT) 6.71 5.77 79 1.2 0.249 6.71 5.77 78 1.2 0.249
5 months vs. baseline 10.01 4.28 90 2.3 0.021 10.01 4.28 90 2.3 0.021
12 months vs. baseline 4.02 4.08 90 1.0 0.327 4.02 4.08 90 1.0 0.327
Group × (5 months vs. baseline) –8.02 6.02 90 –1.3 0.186 –8.02 6.02 90 –1.3 0.186
Group × (12 months vs. baseline) –0.22 5.81 90 0.0 0.970 –0.22 5.81 90 0.0 0.970
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Unadjusted Adjusted for site
β SE df t p-value β SE df t p-value
SRS awareness score
Intercept 12.70 0.54 96 23.5 0.000 12.70 0.54 96 23.5 0.000
Group (IMT) 0.86 0.76 79 1.1 0.260 0.86 0.76 78 1.1 0.260
5 months vs. baseline 0.34 0.70 96 0.5 0.631 0.34 0.70 96 0.5 0.631
12 months vs. baseline –0.56 0.65 96 –0.9 0.394 –0.56 0.65 96 –0.9 0.394
Group × (5 months vs. baseline) –0.33 0.99 96 –0.3 0.739 –0.33 0.99 96 –0.3 0.739
Group × (12 months vs. baseline) 1.82 0.94 96 1.9 0.057 1.82 0.94 96 1.9 0.057
SRS cognition score
Intercept 19.02 0.91 96 20.9 0.000 19.02 0.91 96 20.9 0.000
Group (IMT) 0.07 1.28 79 0.1 0.955 0.07 1.28 78 0.1 0.955
5 months vs. baseline 0.40 1.02 96 0.4 0.695 0.40 1.02 96 0.4 0.695
12 months vs. baseline –1.22 0.95 96 –1.3 0.203 –1.22 0.95 96 –1.3 0.203
Group × (5 months vs. baseline) 0.45 1.44 96 0.3 0.758 0.45 1.44 96 0.3 0.758
Group × (12 months vs. baseline) 2.22 1.37 96 1.6 0.109 2.22 1.37 96 1.6 0.109
SRS communication score
Intercept 31.22 1.47 96 21.2 0.000 31.10 1.60 96 19.4 0.000
Group (IMT) 2.43 2.07 79 1.2 0.243 2.50 2.06 78 1.2 0.228
5 months vs. baseline 2.99 1.82 96 1.6 0.104 2.97 1.82 96 1.6 0.106
12 months vs. baseline 0.93 1.70 96 0.6 0.586 0.90 1.70 96 0.5 0.597
Group × (5 months vs. baseline) –1.54 2.57 96 –0.6 0.552 –1.55 2.57 96 –0.6 0.549
Group × (12 months vs. baseline) 0.26 2.46 96 0.1 0.916 0.25 2.46 96 0.1 0.918
SRS motivation score
Intercept 15.28 0.88 96 17.4 0.000 15.27 0.88 96 17.4 0.000
Group (IMT) 0.48 1.23 79 0.4 0.697 0.48 1.23 78 0.4 0.697
5 months vs. baseline 1.07 0.99 96 1.1 0.283 1.07 0.99 96 1.1 0.283
12 months vs. baseline 0.88 0.92 96 1.0 0.345 0.88 0.92 96 1.0 0.345
Group × (5 months vs. baseline) –1.84 1.40 96 –1.3 0.193 –1.84 1.40 96 –1.3 0.193
Group × (12 months vs. baseline) –1.29 1.34 96 –1.0 0.336 –1.29 1.34 96 –1.0 0.336
SRS mannerisms score
Intercept 16.67 1.07 95 15.6 0.000 16.67 1.07 95 15.6 0.000
Group (IMT) 3.11 1.51 79 2.1 0.043 3.11 1.51 78 2.1 0.043
5 months vs. baseline 3.95 1.09 95 3.6 0.000 3.95 1.09 95 3.6 0.000
12 months vs. baseline 1.82 1.03 95 1.8 0.082 1.82 1.03 95 1.8 0.082
Group × (5 months vs. baseline) –4.20 1.54 95 –2.7 0.008 –4.20 1.54 95 –2.7 0.008
Group × (12 months vs. baseline) –1.15 1.48 95 –0.8 0.439 –1.15 1.48 95 –0.8 0.439
df, degrees of freedom; SE, standard error.
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